Sodium Glucose Co-Transporter 2 Inhibitors Use in Diabetic Patients with Cirrhosis Improves Liver-related Outcomes and Survival.

Sajid Jalil¹, Khurram Bari², Khalid Mumtaz³, Ahmed Ibrahim⁴, Talal K Bhatti⁵, Suvisesh Pothuraju⁶, Mohammad Adam⁷, Honor S Magon⁸, Nikki Duong¹, Paul Y Kwo¹

¹Stanford University School of Medicine, Palo Alto, USA.

²University of Cincinnati, OH, USA.

³The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

⁴Medical University of South Carolina, Charleston, SC, USA.

⁵Northwell University, NY, USA.

⁶University of Louisville, KY, USA.

⁷Kansas University Medical Center, Missouri, USA.

⁸Atropos Health, NY, USA.

PubMed DOI

Abstract

BACKGROUND: The liver outcomes of SGLT-2 inhibitor (SGLT-2i) in T2DM patients with cirrhosis have not been well studied. METHODS: We conducted a retrospective cohort study (January 1, 2010-December 31, 2025) using two databases. Adults ≥ 18 years with type 2 diabetes mellitus (T2DM) and cirrhosis newly treated with SGLT-2i were identified. Patients were grouped into those receiving SGLT-2i and th…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.